Evaluation of the rationality of drugs use inpatient patients with type 2 diabetes mellitus of 2023 at Hospital Y Depok
DOI:
https://doi.org/10.35814/jifi.v23i1.1694Keywords:
Evaluation, Rationality, Type 2 Diabetes MellitusAbstract
Diabetes mellitus is a chronic disease caused by failure to control blood glucose levels. Type 2 Diabetes Mellitus (T2DM) is a condition of hyperglycemia caused by the failure of insulin to maintain balanced blood sugar levels. If T2DM is not treated it will cause complications. One way to control T2DM is the rational use of antidiabetic drugs. This study aims to look at the demographic data of inpatients with T2DM, patterns of drug use, rationality for drug use, and the relationship between the rationality of drug use and therapeutic outcomes in inpatients with T2DM at Hospital Y Depok for the period 2023. The outcome evaluated is a random blood sugar test. The research method was carried out descriptively and inferentially with a cross-sectional design. There were 122 samples that met the inclusion criteria, women predominantly suffered from type 2 diabetes mellitus (50.89%). The most common age range was 46-65 years (64.56%). As many as 84.31% of patients used the JKN payment method. The most widely used class of type 2 diabetes mellitus medication is insulin. In evaluating the rationality of using type 2 diabetes mellitus drugs, the rationality results were 99.49% correct drug, 100% correct dose, and 98.73% correct administration. The results of statistical tests show that there is a correlation between the rationality of drug use and clinical outcomes p-value 0.001.
References
Downloads
Published
Issue
Section
License
Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.
This licence applies to Author(s) and Public Reader means that the users mays :
- SHARE:
copy and redistribute the article in any medium or format - ADAPT:
remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication) - ALIKE:
If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original. - NO ADDITIONAL RESTRICTIONS:
You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
It does however mean that when you use it you must:
- ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
You may not:
- NONCOMMERCIAL: You may not use the article for commercial purposes.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

















